Celgene Had the Highest R&D Spend in 2018

Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData’s Company Financials database.

An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D. Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend.

Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue. GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.”

Top 20 companies by R&D spend as a percentage of annual revenue (click to enlarge)

Roche adds “R&D spend is increasing, but its return is decreasing, mostly due to the high cost of late-stage drug development. Despite having an annual revenue more than three and a half times greater than Celgene’s, GSK has seven drugs in the pre-registration phase compared to Celgene’s eight at the same stage of development.”

Regeneron, in second place for percentage R&D spend/annual revenue (32.6%), and Gilead in fifth place (21.9%), are notable for their traditional core pharma business structure, while other companies in the top 20 are multinational conglomerates.

Roche concluded “The acquisition of Celgene by BMS closed on November 20, 2019, valued at $74 billion. Notably, the acquisition itself takes a gamble on R&D, and contingent value rights (CVRs) issued with Celgene’s shares mean that profitability is hinged on the success of pipeline drugs ozanimod, liso-cel and bb2121. Already placing third for percentage R&D spend/annual revenue pre-acquisition, it seems BMS decided to bolster spending with more spending. Spare cash, decreasing valuations and key patent losses in the last few years may well have spurred this acquisition from BMS’s side.”

To gain access to our latest press releases: GlobalData Media Centre

Analysts available for comment. Please contact the GlobalData Press Office:

Email: pr@globaldata.com
EMEA & Americas: +44 (0)207 832 4399
Asia-Pacific: +91 40 6616 6809

To gain access to our latest press releases and expert analysis on developments in your industry, please connect with us on:

GlobalData | LinkedIn | Twitter

4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.